Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 454,259 shares of the biotechnology company’s stock, valued at approximately $3,330,000.

Several other institutional investors have also modified their holdings of AUPH. SG Americas Securities LLC increased its holdings in Aurinia Pharmaceuticals by 4,307.9% during the 3rd quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock worth $4,015,000 after purchasing an additional 535,301 shares during the period. Stonepine Capital Management LLC purchased a new position in shares of Aurinia Pharmaceuticals during the second quarter worth about $1,713,000. AQR Capital Management LLC purchased a new position in Aurinia Pharmaceuticals during the 2nd quarter worth approximately $1,155,000. Algert Global LLC increased its holdings in shares of Aurinia Pharmaceuticals by 106.8% in the 2nd quarter. Algert Global LLC now owns 193,804 shares of the biotechnology company’s stock valued at $1,107,000 after acquiring an additional 100,104 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in shares of Aurinia Pharmaceuticals by 18.8% in the second quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company’s stock valued at $2,791,000 after buying an additional 77,510 shares during the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Finally, StockNews.com raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Aurinia Pharmaceuticals has an average rating of “Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Stock Up 1.0 %

AUPH stock opened at $8.86 on Monday. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.71 and a 12 month high of $9.74. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The company’s 50 day simple moving average is $7.43 and its 200-day simple moving average is $6.35. The firm has a market capitalization of $1.27 billion, a PE ratio of -59.06 and a beta of 1.45.

Insiders Place Their Bets

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the sale, the director now owns 13,356 shares in the company, valued at approximately $112,591.08. This trade represents a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.30% of the stock is currently owned by company insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.